Alzheimer's disease (AD) is the most common form of dementia and is associated with the 19 accumulation of amyloid-β (Aβ), a peptide whose aggregation has been associated with neurotoxicity. 20 Drugs targeting Aβ have shown great promise in 2D in vitro models and mouse models, yet preclinical 21 and clinical trials for AD have been highly disappointing. We propose that current in vitro culture 22 systems for discovering and developing AD drugs have significant limitations; specifically, that Aβ 23 aggregation is vastly different in these 2D cultures carried out on flat plastic or glass substrates vs. in a 24 3D environment, such as brain tissue, where Aβ confinement very likely alters aggregation kinetics and 25 thermodynamics. In this work, we identified attenuation of Aβ cytotoxicity in 3D hydrogel culture 26 compared to 2D cell culture. We investigated Aβ structure and aggregation in solution vs. hydrogel using 27
Introduction

39
Amyloids are defined as abnormal fibrous, extracellular, protein aggregates that accumulate in 40 organs throughout the body. Native proteins misfold, and intrinsically-disordered proteins fold 41 predominantly into a β-sheet conformation. Under certain conditions the β-sheet structure extends, 42 leading to the formation of amyloid fibrils; this aggregation process either leads to loss of function of the 43 native protein or gain of toxic function of the aggregated amyloid protein. There are currently 37 human 44 amyloid proteins identified that are linked to neurodegenerative diseases and amyloidosis diseases [1, 45 2 ]. Alzheimer's disease (AD) is the most common form of dementia [3] and is associated with the 46 accumulation of amyloid-β (Aβ), and intrinsically disordered peptide between 39 to 45 amino acids long 47 in its native form, whose aggregation has been associated with neurotoxicity in AD [4] . 48
Since the first studies demonstrating a genetic link between Aβ and early-onset AD [5], 49 investigators have targeted Aβ as a potential therapeutic strategy. Neurology has the third highest 50 number of medications in drug development, yet there are only four unique drugs approved by the FDA 51 for the treatment of AD [6] . Between 2002 and 2012 there were 413 clinical trials for AD. During that 52 time only one drug was licensed by the FDA, a 99.6% failure rate [7] . Many AD drugs are Aβ targeting 53 antibodies that demonstrated promise in pre-clinical trials and mouse models yet failed to show efficacy 54 in human patients [8, 9] . 55 There are a number of possible causes for the failure of Aβ targeting drugs in clinical trials. Aβ 56 may not be causative in AD, but instead may simply be a side-product of the disease progression. The 57 clinical trial design may be faulty in that drug intervention is administered in late-stage AD while Aβ toxic 58 effects occur significantly before (potentially decades before) the onset of symptoms. Clinical endpoints 59 are subjective, making it difficult to determine the efficacy of any intervention. Alternatively, the 2D 60 tissue culture models used to screen drugs for their ability to attenuate Aβ toxicity are poor models for 61 the in vivo 3D environment. Some or all of the above hypotheses may be valid; however, in this study, 62
we set out to test the last hypothesis, that 2D tissue culture models are a poor model for Aβ toxicity 63 testing. 64
In vitro models typically culture cells on a 2D surface to study the cellular response to Aβ [10-65 15 ]. However, 3D biomaterial scaffolds promote stem cell differentiation, cellular binding, and cell 66 signaling that better represent in vivo cell behaviors compared to 2D cultures [16] [17] [18] [19] [20] [21] [22] [23] [24] . There is a growing 67 trend across all of biotechnology and biopharmaceutical discovery teams to use 3D models of tissue as 68 opposed to 2D tissue culture models, with remarkably good results [25] [26] [27] . 3D AD models have begun 69
to be used to model the human cellular aspects that mouse models inherently cannot. [28] [29] [30] [31] . Some of 70 these 3D models have used iPSCs taken from an AD patient and differentiated them into neurons that 71 In this work, we tested the hypothesis that Aβ toxicity is altered for cells cultured in 3D 92 hydrogels vs. 2D cell culture plates. We show that Aβ aggregates more readily in the 3D confined 93 environment of a hydrogel. We suggest the differences in toxicity between 2D and 3D cultures are a 94 result in a shift in chemical equilibrium from oligomer to fibril, and from toxic to less toxic species, in 95 these environments. Finally, we propose that some clinical trials of AD drugs fail as a result of the 96 differences in the biophysical environment in 2D culture and the in vivo environment; therefore, we 97 suggest that future Aβ toxicity studies be conducted in 3D hydrogel cultures so that the biophysics of Aβ 98 aggregation better approximates the in vivo scenario. 99 In order to break any existing β-sheet structures and monomerize the protein, lyophilized Aβ 107 was pretreated with hexafluoro-2-propanol at a concentration of 1 mg/ml for 40 mins until Aβ was fully 108 dissolved. Aβ aliquots were transferred into glass scintillation vials, and hexafluoro-2-propanol was 109 evaporated under vacuum overnight. Aliquots of dried peptide film were stored at -20ᵒC. For an 110 experiment, an Aβ aliquot was dissolved in freshly-made and filtered 60 mM NaOH and allowed to 111 dissolve for 2 mins at room temperature. Tissue culture grade water was then added, and the vial was 112 sonicated for 5 mins. The Aβ solution was then filtered with a 0. 
Materials and
Where ( ) = ( ) − 〈 ( )〉 is the fluorescence fluctuation determined from the measured 170 fluorescence intensity, ( ) , at time t, and the average intensity, 〈 ( )〉, over the period of 171 measurement. The excitation laser, which is focused, is assumed to have a 3D Gaussian profile, with a 172 characteristic radial dimension (w 0) and a characteristic axial dimension (z0). For a solution of n 173 noninteracting, freely diffusing fluorescent species G(τ) is given by: 174
Here the Di values are the n different values of diffusion constants and bi are the relative 177 fractions in brightness of these species. In practice, the radial and axial dimensions were determined 178 using Alexa 488 dye in water where the diffusion coefficient (430 µm 2 /s) is known and was used to we expected Aβ to be more toxic to cells in 3D than in 2D. To begin to test this hypothesis, we 230 examined the toxicity of PC12 cells when dosed with Aβ (pretreated to remove β-sheet structure) in 231 both 2D and 3D collagen over a 72 hr period. 232 
241
We acknowledge that the percent viability decreases for all samples over time, but it is 242 important to note that the medium was not changed in order to better mimic the evolving population of 243 Aβ species measured in the ThT and FCS experiments. Over 72 hrs, it is likely that cell waste accumulates 244 and nutrients are depleted, thus explaining the decrease in cell viability in all conditions. The number of 245 viable cells cultured in 2D with 20 µM pretreated Aβ decreased significantly by 24 hrs where the cell 246 viability was 49% (p-value 0.004); at 48 hrs and 72 hrs the cell viability was only 16% (p-value <0.001) 247 and 12% (p-value <0.001) respectively (Figure 1a ). When cells were encapsulated within 3D collagen 248 hydrogels, treatment with Aβ did not affect cell viability (Figure 1b 
TEM imaging of Aβ in solution 254
Given the well-known correlation between Aβ structure or aggregation state and toxicity, we 255 sought to confirm that the Aβ used in these studies aggregated as expected and that the surprising cell 256 viability results were not the result of some anomalous aggregation process. To this end, we performed 257 TEM imaging of the pretreated Aβ at time points after dissolution relevant to the viability studies. 258 
Solution timepoints were collected over 8 hrs; a representative curve is shown (long dash, orange). 292
Collagen hydrogel timepoints were collected over 4 hrs; a representative curve is shown (short dash, 293 purple). There is a significant difference between the MEMFCS calculated G(τ) of solution and collagen 294 gel, p-value: 0.0004 (solution n=6; collagen n=6). 295
The correlation functions were also analyzed using the MEMFCS program, which attempts to 296 determine the distribution of size of the aggregating solutions. A distribution of multiple diffusivity 297 populations of Aβ aggregates and their relative fractions were modeled. In solution, Aβ diffusivity values 298 have a single broad distribution with an average peak diffusivity of 90 µm 2 /s (Figure 4, solution) . The 299 peak diffusivity of Aβ in solution is ~2x slower than the Scr Aβ diffusivity, suggesting an Aβ population 300 predominately composed of dimers. In the hydrogel, Aβ has a peak diffusivity of 60 µm 2 /s, which is ~2x 301 slower than the Scr monomer (129 µm 2 /s). However, in contrast to the solution samples that only have 302 one diffusivity peak, the hydrogel sample data show a small secondary diffusivity peak as early as 5 mins 303 after addition of Aβ to the hydrogel and persists throughout the measurement period (up to 4 hrs) with 304 diffusivity values in the range of 0.2 µm 2 /s to 3 µm 2 /s, or between 650x to 45x slower than Scr Aβ 305 (Figure 4 Figure 5 for Aβ aggregation in 319 solution and collagen hydrogels. In solution, fibrillar Aβ aggregation (signified by ThT fluorescence) has 320 a lag phase during the first ~20 hrs, followed by rapid aggregation (Figure 5, orange) . In hydrogels, 321 however, fibrillar aggregation does not show a lag phase, and instead, fluorescence steadily increases 322 from the initiation of the experiment (Figure 5, purple) . Depending upon the supplier and lot of Aβ 323 tested, these curves lag time, and fluorescence intensity varied, but the qualitative differences between 324 fibril Aβ aggregation in solution and the collagen hydrogel persisted; fibril aggregation was accelerated 325 in the hydrogel compared to the solution. 326
Figure 6 Aβ and collagen concentration impact ThT aggregation kinetics. 328
ThT aggregation kinetics comparing Aβ concentrations (10 µM, light ; 25 µM, medium ; 50 µM, dark 329 ) in solution (a, orange) and collagen hydrogel (b, purple). In c, Aβ aggregation kinetics is compared in 330 hydrogels with collagen concentrations of 0.5 mg/ml (blue; ), 1 mg/ml (green; ), 1.5 mg/ml (yellow; 331 ), and 2 mg/ml (red; ). 332
In solution samples, the duration of the aggregation lag phase varied with Aβ concentration: 333 greater Aβ concentrations correlated with shorter lag phases of fibril aggregation in solution. The lag 334 phase lasted 7.5 hrs for 10 µM Aβ, 4 hrs for 25 µM Aβ, and only 1 hr for 50 µM Aβ (Figure 6a ). This 335 effect was also noted for hydrogels, but on a much faster timescale: the lag phase was 1 hr for 10 µM 336 Aβ, and nonexistent for 25 µM and 50 µM Aβ (Figure 6b ). The rate of fibril aggregation was also 337 influenced by the collagen concentration of the hydrogel: at collagen concentrations of 0.5, 1, 1.5 and 2 338 mg/ml, the lag phases were observed to be 13.5 hrs, 9.5 hrs, 9 hrs, and 6.5 hrs, respectively (Figure 6c) . 339 In the work presented here, our 2D cell culture of PC12 cells demonstrated the expected 357 cytotoxic nature of Aβ aggregates. However, when PC12 cells and Aβ were encapsulated within 3D 358 collagen hydrogels, the cytotoxic effects were attenuated. We supposed that this effect could be due to 359 one of two effects, either (1) the 3D environment altered the phenotype of the PC12 cells, making them 360 less susceptible to Aβ, or (2) the 3D environment altered the aggregation of Aβ. Given that PC12 cells 361 and other neuron-like cells take on a phenotype more closely associated with an in vivo neuron in 3D 362 [22, 23, 84] , we assumed that our first hypothesis was less probable. Therefore, in this work, we set out 363 to investigate how the 3D collagen hydrogel environment affects Aβ structure and aggregation. 364
Discussion
We used a combination of biophysical methods to investigate Aβ structure and aggregation 365 both in solution and in the 3D collagen hydrogel. TEM micrographs of pretreated Aβ that underwent 366 aggregation in solution confirm that the structures seen during our experiments are typical of those 367 seen by others [85, 86] . The pretreatment process removed any observable fibril or protofibril 368 structures (Figure 2a ). FCS and ThT measurements at these early time points (<24 hrs) suggest that only 369 small, rapidly diffusing species remained after Aβ pretreatment; the samples were devoid of any 370 extended β-sheet structures (Figures 3a, 4 , and 5, respectively). These results are consistent with 371 literature reports for Aβ pretreatment via this method [59, 71] . Shortly after the dissolution of Aβ, the 372 Aβ in solution appeared to form dimer or similar diffusing species (Figure 4, solution) , and other 373 somewhat larger aggregated species with diffusivity values on the order of 20 µm 2 /s (Figure 3a) . The 374 observance of monomers and dimers in equilibrium at early stages of aggregation of Aβ in solution has 375 been seen via other methods including chromatography [87, 88] and hydrogen exchange mass 376 spectrometry and others [89, 90] . The observance of larger aggregated species in Aβ solutions that are 377 non-fibril (i.e., they do not bind ThT; Figure 5 ), such as the more slowly diffusing species seen in FCS 378 ( Figure 3a ) and TEM micrographs (Figure 2b) , is consistent with the formation of the toxic oligomer 379 species. While there is considerable debate concerning the actual size and structure of the most toxic 380 species of aggregated Aβ, most consider that this species is smaller than a fibril [91], and by some 381 accounts, the diffusivity of the toxic Aβ species is on the order of 20 µm 2 /s [63, 92] . Aβ aggregated for 382 72 hours shows typical fibril structures via TEM (Figure 1c ), that bind ThT ( Figure 5 ), as would be 383 expected for large extended β-sheet structures [93] . Given the typical aggregation pathway, we 384 observed of Aβ in solution -one that included detectable oligomers that are suggested to be the most 385 toxic species -the viability results observed in 2D cell culture (Figure 1a & 1c) were expected. 386
The same careful biophysical examination of Aβ aggregation in 3D collagen hydrogels 387 demonstrates that aggregation does not proceed through the same pathway as in solutions. Even at 388 early times during aggregation, no slowly diffusing species (diffusivity ~20 µm 2 /s) were observed 389 (Figures 3b, 4) . At these early times during aggregation, only a small unaggregated species and a very 390 large/slow diffusing species were observed; the larger species diffused 10x to 100x more slowly than the 391 oligomer observed in solution (Figures 3, 4) . Given the ThT fluorescence seen even at these early times 392 ( Figure 5 ), this larger species may be a fibril form of Aβ. We hypothesize that we did not observe any 393 notable Aβ toxicity in 3D culture because Aβ aggregation proceeded through a pathway that did not 394 include the formation of any detectable oligomeric species that are typically associated with Aβ toxicity. 395
While we are not aware of any other studies of Aβ aggregation in a 3D environment, the effect 396 of crowding and confinement on protein folding and aggregation has been previously studied [41, 48] . 397 Biomaterial scaffolds are composed of self-associating or crosslinked structures that exert an excluded 398 volume effect on soluble molecules that are entrapped within. The excluded volume effect increases the 399 local concentration of soluble molecules, increasing the chance of protein-protein interactions. The 400 reduced volume also confines the available space a protein may use to fold, promoting a more compact, 401 low entropy conformation. Uncrosslinked crowding molecules such as PEG, Ficoll, and bovine serum 402 albumin stabilize protein folding into functional states or accelerate aggregation in aggregation-prone 403 proteins (e.g., lysozyme, α-synuclein, and β2-microglobulin) [44, 45, 48] . Confinement has a greater 404 stabilization effect than crowding but is seldom used to study the biophysics of proteins [39, 94, 95] . We 405 suggest that in our studies, the confinement provided by the 3D collagen hydrogel resulted in increased 406
Aβ-Aβ interactions, thus leading to the observed faster aggregation kinetics and the lack of slower 407 diffusing species. If this were the case, then we would expect to see that higher concentrations of Aβ 408 shortened the lag time to the onset of rapid aggregation due to the greater probability of nucleation of 409 aggregation. This is indeed what we observed (Figure 6a and b ). At every concentration tested, the lag 410 phase until the onset of rapid aggregation was significantly shorter in 3D environments and shorter at 411 higher Aβ concentrations. The acceleration of aggregation of Aβ with increasing concentrations of 412 collagen in the 3D hydrogels ( Figure 6c) is consistent with the hypothesis as well; higher collagen 413 concentrations would lead to smaller void spaces in the 3D collagen hydrogel, thus greater confinement, 414 increased Aβ-Aβ interactions, and acceleration of Aβ aggregation. 415
When Aβ aggregation is nucleated in a confined environment, the β-sheet structures that form 416 are more stable vs. aggregation as free molecules in solution, resulting in faster filament growth. Such 417 stabilization of β-sheet structured Aβ aggregates that occurs in collagen hydrogels should result in a 418 shift in the chemical equilibrium of aggregate species. In solution, the equilibrium composition of Aβ 419 species is expected to be a distribution of unstructured monomer-dimer -multimer species. In confined 420 collagen hydrogels, however, we hypothesize (and our data support) that the equilibrium is shifted to 421 stable β-sheet aggregates and away from the relatively unstable/unstructured presumed toxic 422 oligomeric Aβ species. 423
We propose that the attenuation of Aβ toxicity observed in the 3D environment is due to the 424 shift in aggregation kinetics of Aβ away from the smaller toxic oligomer. However, other explanations 425 are also plausible. Aggregated Aβ species may have hindered diffusion in the 3D collagen hydrogel. The 426 FCS data suggest that at least at early times the Aβ species do diffuse within the hydrogel. In addition, 427 the mesh size of the 3D collagen hydrogels used in this study was ~10 µm, one to two orders of 428 magnitude larger than reports of sizes of Aβ toxic oligomers [96, 97] . Therefore, we do not conclude that 429 hindered diffusion of Aβ within the hydrogel contributed significantly to the attenuation in Aβ toxicity 430 observed in 3D compared to 2D environments. It is also possible that the 3D environment resulted in 431 some unexpected phenotypic change in the PC12 cells that we cannot rule out in the studies performed 432 in this work. 433
The shift in the equilibrium of Aβ species away from smaller potentially toxic species to larger 434 extended β-sheet species in confined environments observed in our studies may suggest similar 435 phenomena in vivo tissues. At the very least, our studies suggest that Aβ aggregation kinetics are 436 fundamentally different in 3D structures as compared to in the solution phase of 2D culture, making a 437 direct translation of results from a 2D culture model to a more in vivo-like 3D culture model difficult. 438
However, this relatively simple collagen hydrogel cannot recapitulate the complexity of the in vivo 439 environment. We can only speculate that the high percentage of failed Aβ targeting drugs in clinical 440 trials may be due to the drug discovery models missing essential properties such as confinement and 441 dimensionality. Knowing the biophysical impact of confinement stabilizing toxic Aβ aggregate species, 442 advanced 3D in vitro models may be developed to investigate AD pathology and be implemented in AD 443 drug development. 
